ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
February 10, 2021NeuroRx, Inc. reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG (SIX:RLF;OTCQB:RLFTF) in patients with respiratory failure due to ... -
NeuroRx Initiates Study of Inhaled ZYESAMI for Severe COVID-19 with UCI Health
February 09, 2021NeuroRx announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine. -
NeuroRx, Relief, and Quantum Leap Announce Inclusion of ZYESAMI in I-SPY COVID-19 Trial
January 15, 2021NeuroRx, Relief Therapeutics, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100TM: aviptadil) in the I-SPY COVID-19 ...
Pharma Sources Insight January 2025
